Clinical trial NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Official title: A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Participants Followed by a Phase 2a Open Label Study in Participants with PNH and Residual Anemia to Evaluate the Safety, Tolerability, PK and PD of ADX-038
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Keywords: siRNA
PNH
Lead sponsor: ADARx Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
Collaborators: name: ADARx Australia Pty Ltd
name: Novotech (Australia) Pty Limited
First posted: 2023-05-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Model Description
Primary purpose: TREATMENT

Brief summary: The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in both healthy participants (HP) and in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Detailed description: The clinical study described in this protocol is a Phase 1/Phase 2a study evaluating safety, tolerability, PK, and PD of ADX-038.

The study consists of 2 parts:

1. Phase 1 - Randomized, double-blind, placebo-controlled, parallel group, single ascending dose (SAD) in HP with up to 5 dose cohorts.
2. Phase 2a - Open label, single-arm (ADX-038), 2 dose study in participants with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia on a standard-of-care (SOC) anti-C5 regimen of ravulizumab or eculizumab.

Eligibility criteria: Phase 1 Key Inclusion Criteria

* 18 to 55 years of age
* Participants who are healthy as determined by medical evaluation
* History of recent meningococcal, pneumococcal and Haemophilus influenzae type B vaccinations or willing to be vaccinated
* Screening tests negative for illicit drug, nicotine, and alcohol use

Phase 1 Key Exclusion Criteria

* History of any significant medical conditions, except for completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia without evidence of recurrence within the prior 3 months
* Any viral, bacterial, parasitic, or fungal infection within the prior 30 days
* Frequent respiratory, nasopharyngeal or ear infections (more than 5 infections per year)
* History of environmental exposure or sick contact that increase the risk of meningococcal, pneumococcal and/or Haemophilus influenza type B infections
* Complement deficiency or immunodeficiency syndrome
* Major surgery or significant traumatic injury within the prior 3 months
* History of anaphylaxis or hypersensitivity reactions
* History of penicillin allergy
* History of splenectomy
* History of alcohol abuse or illicit drug use
* Donated plasma within the prior 7 days
* Donated blood or loss more than 400 milliliters of blood (excluding blood volume drawn at screening) within the prior 90 days
* Screening estimated creatinine clearance of less than 60 milliliters per minute
* Screening hematology, serum chemistry, or coagulation parameters that are outside the normal range
* Screening vital signs that are abnormal per protocol specification
* Screening electrocardiogram findings that are clinically significant
* Pregnant or lactating females
* Use of prescription (except for contraceptives and study-related prophylactic antibiotics) or over-the counter medications (except for paracetamol or ibuprofen) or vitamins/supplements within the prior 7 days
* Use of medications that may reduce the effectiveness of hormonal contraceptives within the prior 28 days
* Use of an investigational therapeutics within the prior 30 days or within the expected washout (at least 5 half-lives)
* Unwilling or unable to adhere to study-related prophylactic antibiotics requirements

Phase 2a Key Inclusion Criteria

* at least 18 years of age
* Diagnosis of paroxysmal nocturnal hemoglobinuria based on documented clone size
* Hemoglobin concentration of less than 12 gram per deciliter
* History of recent meningococcal, pneumococcal and Haemophilus influenzae type b vaccinations or willing to be vaccinated
* On a stable anti-C5 regimen for greater than or equal to 12 weeks prior to Day 1

Phase 2a Key Exclusion Criteria

* Any viral, bacterial, parasitic, or fungal infection within the prior 14 days
* HIV, active hepatitis C or hepatitis B infection
* History of meningococcal or tuberculosis infection
* History of malignancy in the past 5 years, except for completely excised non-melanoma skin cancer or low grade cervical intraepithelial neoplasia with no evidence of recurrence within the prior 3 months
* Complement deficiency syndrome
* History of hematopoietic stem cell transplantation
* History of splenectomy
* Inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, or chronic liver disease
* Clinically significant and uncontrolled medical conditions including, but not limited to, thromboembolic disease, acute coronary syndrome, and diabetes
* Pregnant or lactating females
* Use of an investigational therapeutics within the prior 30 days or within the expected washout period (at lest 5 half-lives)
* Abstain from alcohol consumption for 48 hrs before day of dosing and restrict to no more than an average of 14 standard drinks per week

Primary outcomes:
measure: Safety in Healthy Volunteers
timeFrame: 365 days
measure: Safety in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
Secondary outcomes:
measure: Pharmacokinetics in Healthy Participants
timeFrame: 8 days
measure: Pharmacodynamics in Healthy Participants
timeFrame: 365 days
measure: Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 365 days
measure: Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 365 days
measure: Pharmacodynamics in Healthy Participants
timeFrame: 365 days
Other outcomes:
measure: Immune Response in Healthy Participants
timeFrame: 365 days
measure: Pharmacodynamics in Healthy Participants
timeFrame: 365 days
measure: Safety in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Clinical Effect in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Effects on Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 8 days
measure: Pharmacodynamics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 365 days
measure: Immune Response in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Efficacy in Paroxysmal Nocturnal Hemoglobinuria Participants
timeFrame: 365 days
measure: Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 8 days
measure: Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 8 days
measure: Pharmacokinetics in Paraxysmal Nocturnal Hemoglobinuria
timeFrame: 8 days
Locations:
city: Brisbane
country: Australia
facility: Nucleus Network Brisbane
state: Queensland
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
state: Victoria
city: Parkville
country: Australia
facility: Royal Melbourne Hospital
state: Victoria
city: London
country: United Kingdom
facility: Richmond Pharmacology Ltd
Study officials:
References: